You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
內地第三批國家藥品集中採購開標 擬中選產品均價降53%
阿思達克 08-21 07:38
內地採購規模達數百億元人民幣的第三批國家組織藥品集中採購在上海開標,並產生擬中選結果。此次採購共有189家企業參加,產生擬中選企業125家,擬中選產品191個,擬中選產品平均降價53%,最高降幅95%。

擬納入56個品種、涉及300多個品規,第三批國家集採最終有55個品種採購成功,藥品品種數量接近前兩批之和。與第二批國家集採相比,第三批採購規則僅做微調優化,最大可中選企業數量從原來的6家增加到8家。

國家醫保局醫藥價格和招標採購司負責人表示,第三批國家集採堅持高質量標準,仍將通過質量一致性評價作為仿制藥入圍的條件。國家組織藥品集中帶量採購對患者達到減負擔、提質量、強保障等效果,對醫藥企業產生降成本、穩需求、助推廣、促研發的作用,既保障民生,亦促進產業轉型升級。(ta/w) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account